Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Teams Up With Johns Hopkins To Tackle Cardiac Disease In India

This article was originally published in PharmAsia News

Executive Summary

Medtronic and Johns Hopkins University’s Center for Bioengineering Innovation and Design are joining forces to develop medical devices for developing countries, starting in India, as part of a Medtronic grant.

You may also be interested in...



CDRH Focusing On New PMA Pathway, Clinical Trials Program In 2014/2015 Priorities

CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.

FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance

In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA had waited.

Diabetes Tech Society Gets FDA Buy-In For Glucose Monitor Surveillance Program

The proposed surveillance program would test marketed blood glucose monitor systems to ensure they are performing at the level expected when they were cleared. It was met with support from FDA, device companies, academics and patient advocates.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC085050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel